Contrasting SI-BONE (NASDAQ:SIBN) and Autonomix Medical (NASDAQ:AMIX)

SI-BONE (NASDAQ:SIBN) and Autonomix Medical (NASDAQ:AMIX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings and target prices for SI-BONE and Autonomix Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SI-BONE	0	0	6	0	3.00
Autonomix Medical	0	0	1	0	3.00

SI-BONE presently has a consensus target price of $24.50, suggesting a potential upside of 66.10%. Autonomix Medical has a consensus target price of $28.00, suggesting a potential upside of 1,413.51%. Given Autonomix Medical’s higher probable upside, analysts plainly believe Autonomix Medical is more favorable than SI-BONE.

Profitability

This table compares SI-BONE and Autonomix Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SI-BONE	-23.82%	-22.51%	-16.53%
Autonomix Medical	N/A	-212.48%	-161.13%

Valuation & Earnings

This table compares SI-BONE and Autonomix Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SI-BONE	$167.18 million	3.75	-$43.34 million	($0.76)	-19.41
Autonomix Medical	N/A	N/A	-$15.43 million	($12.93)	-0.14

Autonomix Medical has lower revenue, but higher earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

98.1% of SI-BONE shares are held by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are held by institutional investors. 3.9% of SI-BONE shares are held by insiders. Comparatively, 32.4% of Autonomix Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

SI-BONE has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Autonomix Medical has a beta of -5.4, indicating that its share price is 640% less volatile than the S&P 500.

Summary

SI-BONE beats Autonomix Medical on 7 of the 12 factors compared between the two stocks.

About SI-BONE

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.